Jo, Peter

[["dc.bibliographiccitation.firstpage","400"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","400"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2022-06-08T07:57:20Z"],["dc.date.available","2022-06-08T07:57:20Z"],["dc.date.issued","2013"],["dc.description.abstract","400 Background: The role of the potential stem cell marker CD133 as a predictive or prognostic marker in multimodal rectal cancer treatment is currently under debate. While CD133 has been identified as a prognostic marker in rectal cancers after preoperative radiochemotherapy (RCT) it was recently characterized as a very unspecific feature for colorectal cancer stem cells. We therefore analyzed the association between CD133 expression and mutations in the proto-oncogenes K-Ras and PI3K in rectal cancer patients receiving neoadjuvant RCT. Methods: CD133 expression was evaluated immunhistochemically in pre-treatment biopsies and surgical specimens of 128 patients with locally advanced rectal cancers (cUICC II/III) treated with preoperative RCT within the phase-III German Rectal Cancer Trials. K-Ras mutations were analyzed by sequencing of exons 1, 2, and 3. PI3K mutations were detected by sequencing the p110α subunit (PIK3CA) and correlated with histopathologic parameters, tumor regression and survival. Results: CD133 expression was significantly associated with mutations in the K-Ras gene in both pre-treatment biopsies and post-treatment tumor specimens in uni- and multivariate analyses. However, no significant correlation was observed between CD133 and PI3K mutations. Post-treatment CD133 levels were correlated with neoadjuvant RCT (50.4 Gy/5-FU vs. 50.4 Gy/5-FU+Ox) and tumor regression grading. Anyway, there was no significant association between pre- and post-treatment CD133 expression and disease-free survival. Conclusions: CD133 expression levels are strongly associated with mutations in the K-Ras proto-oncogene in rectal cancers before and after preoperative RCT. Our results strengthen the hypothesis that CD133 is not a specific marker for colorectal stem cells but might be integrated in proliferation pathways like the ras-raf axis."],["dc.identifier.doi","10.1200/jco.2013.31.4_suppl.400"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110058"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Association of CD133 expression levels with the k-ras mutation status in rectal cancers before and after preoperative radiochemotherapy."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","568"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Epping, Ingo"],["dc.contributor.author","Kramer, Frank"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Salinas, Gabriela"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Beissbarath, Tim"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:16:01Z"],["dc.date.available","2018-11-07T10:16:01Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Patients with locally advanced rectal cancer are treated with preoperative chemoradiotherapy followed by surgical resection. Despite similar clinical parameters (uT2-3, uN+) and standard therapy, patients' prognoses differ widely. A possible prediction of prognosis through microRNAs as biomarkers out of treatment-naive biopsies would allow individualized therapy options. Methods: Microarray analysis of 45 microdissected preoperative biopsies from patients with rectal cancer was performed to identify potential microRNAs to predict overall survival, disease-free survival, cancer-specific survival, distant-metastasis-free survival, tumor regression grade, or nodal stage. Quantitative real-time polymerase chain reaction (qPCR) was performed on an independent set of 147 rectal cancer patients to validate relevant miRNAs. Results: In the microarray screen, 14 microRNAs were significantly correlated to overall survival. Five microRNAs were included from previous work. Finally, 19 miRNAs were evaluated by qPCR. miR-515-5p, miR-573, miR-579 and miR-802 demonstrated significant correlation with overall survival and cancer-specific survival (p<0.05). miR-573 was also significantly correlated with the tumor regression grade after preoperative chemoradiotherapy. miR-133b showed a significant correlation with distant-metastasis-free survival. miR-146b expression levels showed a significant correlation with nodal stage. Conclusion: Specific microRNAs can be used as biomarkers to predict prognosis of patients with rectal cancer and possibly stratify patients' therapy if validated in a prospective study."],["dc.identifier.doi","10.3390/ijms17040568"],["dc.identifier.isi","000374585300147"],["dc.identifier.pmid","27092493"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40949"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mdpi Ag"],["dc.relation.issn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","163"],["dc.bibliographiccitation.lastpage","179"],["dc.bibliographiccitation.seriesnr","1381"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Jo, Peter"],["dc.contributor.editor","Grützmann, Robert"],["dc.contributor.editor","Pilarsky, Christian"],["dc.date.accessioned","2021-06-02T10:44:24Z"],["dc.date.available","2021-06-02T10:44:24Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1007/978-1-4939-3204-7_9"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87026"],["dc.notes.intern","DOI-Import GROB-425"],["dc.publisher","Springer New York"],["dc.publisher.place","New York, NY"],["dc.relation.crisseries","Methods in Molecular Biology"],["dc.relation.eisbn","978-1-4939-3204-7"],["dc.relation.isbn","978-1-4939-3203-0"],["dc.relation.ispartof","Methods in Molecular Biology"],["dc.relation.ispartof","Cancer Gene Profiling"],["dc.relation.ispartofseries","Methods in Molecular Biology; 1381"],["dc.title","Cancer Gene Profiling for Response Prediction"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]